US Patent Issued to Viracta Therapeutics, Nantkwest on Sept. 30 for "HDAC inhibitors for use with NK cell based therapies" (California Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,427,152, issued on Sept. 30, was assigned to Viracta Therapeutics Inc. (Cardiff, Canada) and Nantkwest Inc. (Culver City, Calif.).

"HDAC inhibitors for use with NK cell based therapies" was invented by James N. Woody (Cardiff, Calif.) and Patrick Soon-Shiong (Culver City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell."

The patent was filed on July 14, 2017, under Application No. 16/317,7...